Eli Lilly (LLY) recently announced positive results from its Phase 3 BRUIN CLL-313 trial, revealing significant ...

Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential ...

By nailing the primary endpoint in a phase 3 trial, Eli Lilly's Bruton tyrosine kinase (BTK) inhibitor Jaypirca has come one ...

Eli Lilly's approved blood cancer therapy Jaypirca helped delay progression of the disease in previously untreated patients ...

Jaypirca outperformed chemoimmunotherapy in progression-free survival for chronic lymphocytic leukemia patients in a Phase 3 ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-313 clinical trial of ...

Reversible BTK inhibitor Jaypirca (pirtobrutinib) has been shown in the BRUIN CLL-313 to significantly improve ...

Eli Lilly has announced positive topline results from the Phase III BRUIN CLL-313 trial of Jaypirca (pirtobrutinib), sending ...

Investing.com -- Eli Lilly announced that its phase 3 trial of Jaypirca met the primary endpoint in patients with chronic lymphocytic leukemia. The pharmaceutical company said the results from the ...

Eli Lilly ( NYSE: LLY) said on Monday that its late-stage trial testing Jaypirca (pirtobrutinib), compared with chemoimmunotherapy, in patients with chronic lymphocytic leukemia or small lymphocytic ...

Eli Lilly's new TuneLab platform gives biotech firms AI-powered drug discovery tools using $1 billion of proprietary research ...

Complex or unclear enrolment and study procedures can also result in participant abandonment. To mitigate this, researchers ...